FDA's TEMPO Pilot Could Redefine the Future of Digital Health Regulation
- Nexgen Health Group
- Jul 28
- 3 min read
The U.S. Food and Drug Administration (FDA) recently announced the first participant selected for its Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot program, an initiative that could significantly influence how digital health technologies are evaluated and introduced into clinical practice.
Rather than representing a new device approval, the announcement reflects a broader evolution in regulatory thinking—one that recognizes the unique nature of software-driven healthcare technologies.
Moving Beyond Traditional Premarket Evaluation
Historically, most medical devices have followed a familiar regulatory pathway:
Product development
Clinical validation
FDA review
Commercial launch
Digital health technologies, however, evolve much more rapidly.
Artificial intelligence algorithms improve over time, software receives frequent updates, and connected devices continuously generate valuable clinical information after deployment.
Recognizing these differences, the FDA created the TEMPO pilot to explore whether real-world evidence can play a larger role in evaluating digital health technologies while maintaining patient safety.
The First TEMPO Participant
The FDA selected Dexcom as the first manufacturer to participate in the pilot.
Its proposed Dexcom Glucose Health Program combines continuous glucose monitoring with digital health metrics, AI-generated insights, and personalized guidance intended to support metabolic monitoring and early identification of prediabetes and Type 2 diabetes. The FDA will continue evaluating the program's intended use throughout the pilot.
Why Real-World Data Matters
One of the defining characteristics of the TEMPO pilot is its emphasis on Real-World Data (RWD).
Instead of relying exclusively on premarket clinical evidence, participating manufacturers will collect, monitor, and report how their technologies perform in actual healthcare settings.
This information may help regulators better understand:
Clinical effectiveness
Patient outcomes
User behavior
Long-term performance
Opportunities for continuous product improvement
For digital health technologies that evolve through software updates and AI refinement, this represents a more practical method of evaluating ongoing performance.
A New Relationship Between Regulation and Reimbursement
Another notable aspect of the TEMPO pilot is its collaboration with the CMS Innovation Center's ACCESS Model.
Historically, FDA clearance and reimbursement decisions have often progressed independently. Under TEMPO, regulatory evaluation and reimbursement innovation are being explored in parallel.
This coordinated approach could help generate evidence not only for regulatory decision-making but also for demonstrating clinical value within the healthcare system.
What This Means for the Digital Health Industry
Although TEMPO remains a pilot program, it highlights several broader trends that are likely to shape the future of digital health regulation:
Greater reliance on Real-World Evidence
Real-world performance data is becoming increasingly important in demonstrating clinical value and supporting regulatory decision-making.
Continued growth of AI-enabled healthcare
Artificial intelligence is moving beyond standalone algorithms and becoming integrated into broader clinical decision-support platforms.
Regulatory frameworks designed for software
Traditional approval models were built around static medical devices. Future regulatory pathways may become more adaptable to continuously evolving software technologies.
Increased focus on chronic disease management
The initial TEMPO pilot focuses on technologies supporting chronic conditions, including cardio-kidney-metabolic diseases, with additional clinical areas expected as the program expands.
Looking Ahead
The selection of the first TEMPO participant is less about one company's technology and more about the FDA's willingness to explore a modern regulatory framework for digital health.
As software, AI, and connected medical technologies become central to healthcare delivery, regulatory approaches must evolve alongside them.
The TEMPO pilot offers an early glimpse into how future digital health innovations may reach patients—through a combination of real-world evidence, continuous evaluation, and closer integration between regulatory oversight and healthcare delivery.
For companies developing AI-powered medical technologies, Software as a Medical Device (SaMD), or connected health platforms, this program may become one of the most important regulatory developments to watch over the coming years.
Comments